Introduction

The gap in medical knowledge between ischaemic and haemorrhagic type of stroke is surprising. Whereas the ischaemic side has been extensively evaluated by an impressive amount of pathophysiological studies as well as of clinical trials, intracerebral haemorrhage (ICH) has been so far a relatively neglected medical issue, addressed by a handful of trials.

Such a difference is even more surprising if we consider some epidemiological features of this disease. ICH is a common disorder, with an estimated overall incidence between 12 and 15 cases per 100,000 people each year [1–5], i.e., 37,000–50,000 cases each year in the USA [2, 3]. The most striking data, however, is its 6-month mortality, ranging between 30% and 55%, increasing up to 67% in patients receiving oral anticoagulant therapy (OAT). Moreover, it is a seriously disabling illness, as 80%–90% of survivors are left with dense neurological deficits [1–5].

In this review we will first examine the pathophysiology of ICH in patients with normal haemostasis and in patients in anticoagulant or antiplatelet treatment, and then we will consider the current therapeutic options for both groups of patients.

Pathophysiology of ICH in patients with normal haemostasis

ICH can be defined as an acute and spontaneous bleeding into the brain parenchyma [5]. In more than two-thirds of cases ICH is classified as primary, as it occurs from spontaneous rupture of small vessels damaged by hypertension (60%–70% of cases) or amyloid angiopathy (15% of cases). In a minority of patients ICH results from trauma, vascular abnormalities (arteriovenous malformations and aneurysm) or other causes listed in Table 1. The incidence
of ICH increases exponentially with age, is higher in men than in women and is strongly increased by antiplatelet or anticoagulant therapy [6].

ICH has been considered until recently a monophasic event, in which blood clotting and the tampon effect of the surrounding tissues were able to self-limit the extent of the injury. Such a pathophysiological picture has probably conditioned the medical approach to such a disease, usually oriented to a minimalistic, if not nihilistic, attitude. The landmark prospective study of Brott et al. [7] was the first to demonstrate that an increase in haematoma volume of more than 33% occurs within 3 h from the ICH onset in more than one third of patients, even in the absence of coagulation defects. This process, known as early haematoma growth, is of paramount clinical relevance, as both mortality and functional outcome have been demonstrated to be strictly related to the haematoma volume [8–10]. On these pathophysiological grounds it is very attractive to hypothesise that an early haemostatic treatment might stop ongoing bleeding and improve outcomes [11].

A further mechanism involved in neurological deterioration is the process of perihaematomal brain injury. The development of perihaematoma oedema starts early, in most cases within 3 h from ICH onset, and it progressively increases for at least 72 h [9, 11]. Although apparently paradoxical, the main role in promoting perihaematoma oedema is played by thrombin. Activation of the coagulation cascade with release of thrombin during clotting, indeed, appears to be the triggering event that initiates formation of brain oedema, because thrombin itself is able to activate both inflammation and cytotoxicity and disrupts the blood–brain barrier [12–14].

**Pathophysiology of ICH in patients receiving antithrombotic therapies**

Any antithrombotic treatment negatively affects both the incidence and the prognosis of ICH. Oral anticoagulant treatment (OAT) significantly increases the risk of ICH in comparison with patients who are not on OAT, leading to an estimated incidence as high as 1.8%/year [15–19]. Risk factors for ICH in OAT patients are listed in Table 2. The relationship between intensity of anticoagulation and the risk of ICH is a relevant point. Although International Normalised Ratio (INR) values exceeding 3.5–4 are associated with a higher risk of ICH, the majority of OAT-related ICH (OAT-ICH) occur when the INR is within the therapeutic range [20–22]. Oral anticoagulation with INR to maintain levels between 2 and 3, even if carefully regulated, increases several times the relative risk of ICH, with an absolute risk ranging from 0.3 to 0.6%/year [17–22].

Thus, OAT not only increases the risk, but also worsens the prognosis of ICH, increasing its severity as well as the likelihood of death [23–25]. Although the dynamics of haematoma expansion in OAT-ICH is not fully established, it is reasonable to assume that the persistent coagulopathy may lead to haematoma growth over a longer period than in non-OAT patients [25]. This finding is of great clinical relevance, as it provides the pathophysiological rationale for the treatment of OAT-ICH, which should be aimed to immediately reverse the anticoagulant effect in order to limit haematoma expansion.

In the general perception antiplatelet drugs are very safe, carrying only a small risk of gastrointestinal adverse effects. This perception is not at all correct, because aspirin (the most widely used antiplatelet drug) carries a significant risk of ICH, ranging between 0.2% and 0.3%/patient/year, slightly higher than the estimated absolute rate in the general population [6], not receiving aspirin. Such a figure is further worsened by the combination of clopidogrel and aspirin, which may increase ICH by a clinically relevant magnitude in patients with cerebrovascular diseases [26, 27]. Moreover, it has been recently demonstrated in a population-based study that regular aspirin use before ICH onset increases 2-fold the risk of death, independently from the severity of bleeding [28]. Similar findings had already been obtained in previous studies [29, 30], although they were not confirmed in a very recent one [31]. A possible explanation for the observed increase in mortality is an early enlargement of haematoma because the impairment of the haemostasis lasts for a few days even after aspirin withdrawal [28, 30].

Finally, the association of warfarin and aspirin should be considered. This is a very common clinical problem, as

---

**Table 1 Causes of intracerebral haemorrhage**

| Primary intracerebral haemorrhage (78%–88% of cases) |
|-----------------------------------------------------|
| • Chronic hypertension (60%–70% of cases)           |
| • Cerebral amyloid angiopathy (15% of cases)        |
| Secondary intracerebral haemorrhage                |
| • Trauma                                            |
| • Arteriovenous malformation                        |
| • Intracranial aneurysm                             |
| • Cavernous angioma                                 |
| • Venous angioma                                    |
| • Dural venous sinus thrombosis                     |
| • Intracranial neoplasm                             |
| • Coagulation disorders                             |
| • Vasculitis                                        |
| • Cocaine or heavy alcohol use                      |
| • Haemorrhagic conversion of ischemic stroke        |

**Table 2 Risk factors for developing intracerebral haemorrhage during oral anticoagulant therapy**

- Age (especially over 75 years)
- Hypertension (especially systolic blood pressure >160 mmHg)
- Previous stroke
- INR levels
- Concomitant use of antiplatelet drug
- Cerebral amyloid angiopathy
it has been estimated that approximately 20% of patients taking warfarin for atrial fibrillation also receive antiplatelet drugs for concomitant coronary heart disease [32]. Data about the risk of ICH during this combination therapy are conflicting, as some studies show an increased risk when anticoagulant and antiplatelet therapy are combined [33, 34], whereas others do not [35, 36]. Although the inconsistency of data precludes any evidence-based firm conclusion, it seems reasonable to assume that the ICH risk is further increased by the association of warfarin and antiplatelet drugs.

Emergency treatment of ICH

Recent insights into the pathophysiology of ICH are expected to profoundly modify the treatment of this disease. The key message strongly emerging from the current literature is that “time is brain” [37], and therefore ICH should be regarded and treated as a compelling medical emergency. It is therefore time to leave the minimalist, if not nihilistic, approach to the therapy of ICH that has been the predominant attitude in the past.

Emergency management of ICH patients includes airway management, control of intracranial pressure and treatment of hypertension [38]. The latter point is of great relevance, as extreme hypertension is a common finding within the first hours from ICH onset, and raised blood pressure negatively affects ICH outcome [39, 40], although a recently published study fails to find such an association [41]. Treatment of hypertension can be performed in an emergency setting by intravenous boluses of labetalol (10–80 mg bolus every 10 min, up to 300 mg), whereas in intensive care units blood pressure can be controlled by continuous infusion of labetalol, esmolol or nicardipine [3]. Sodium nitroprusside should be avoided in this setting because of its tendency to raise intracranial pressure through cerebral vasodilatation [42]. As far as intracranial pressure control is concerned, emergency measures to lower it are required for comatose patients as well as for those with signs of cerebral herniation [38]. However, no anti-oedema treatment (steroids, osmotic diuretics, haemodilution) has been demonstrated to reduce mortality and disability in these patients [43–45].

Alongside these supportive therapies should stand aetiological treatments aimed to reduce haematoma size, for instance by surgical removal. The effectiveness of surgical removal of haematoma is still a controversial issue, namely when anticoagulant and antiplatelet therapy are combined [33, 34], whereas others do not [35, 36]. Although the inconsistency of data precludes any evidence-based firm conclusion, it seems reasonable to assume that the ICH risk is further increased by the association of warfarin and antiplatelet drugs.
A dose response is evident, as the difference is significant for higher doses (160 µg/kg), but not for intermediate and lower doses (80 and 40 µg/kg). More interestingly, the reduction in the haematoma growth is accompanied by improved survival and better clinical outcomes in the treated group. Such a beneficial effect is impressive: 90 days mortality is reduced in the rFVIIa group from 29% to 18%, with an odds ratio for survival of 1.8 and a number needed to treat of approximately 9. Equally striking is the effect on severe disability, with a 13% absolute reduction on unfavourable outcomes measured according to the Modified Rankin Scale (odds ratio for improvement 2.2, \( p = 0.0004 \)) and a more than double score on Barthel Index (60.0 vs. 25.0, \( p = 0.006 \)) for the treatment group. On the other hand, fears about the thrombogenic potential of such a powerful haemostatic drug are at least partially borne out. Arterial thromboembolic serious adverse events occur significantly more frequently in the rFVIIa-treated than in placebo-treated patients (5% vs. 0%), primarily as myocardial ischaemic events and ischaemic stroke, half of them occurring in the largest dose group. However, most patients recovered from these complications, and the overall frequency of fatal or seriously disabling ischaemic events does not differ between rFVIIa and placebo.

How can we transfer the results of this innovative trial into everyday clinical practice? Should we modify our guidelines in order to assure every ICH patient has early rFVIIa treatment? If the question is so radically asked, the answer is certainly not, as stated by a recent systematic review from the Cochrane Library [50]. Many issues suggest caution before recommending rFVIIa as the standard of treatment for ICH. First, in this trial there was no adjustment for blood pressure, a factor known to affect the outcome of ICH [38–40], although the trend of this parameter did not differ among the treatment groups. In future trials, great attention should be paid to this issue in order to identify possible interactions of rFVIIa with blood pressure that could modify the magnitude of benefit of this drug in ICH patients. Second, treatment with rFVIIa is effective only in patients treated within 3 h of symptoms onset, whereas in patients treated later no difference in the haematoma growth is found compared to the controls [51]. This suggests that the time window for this intervention is very narrow, and only a subset of ICH patients could benefit from such a treatment. Indeed, a recently published population-based cohort study estimates that only 13%–18% of ICH patients would have qualified for treatment with rFVIIa by Meyer’s trial criteria [52], 2–3 times the rtPA eligibility rate of ischaemic stroke patients [53]. Although the absolute number of treated patients would likely be less than those with ischaemic stroke, it can be postulated that in the USA between 5000 and 9000 ICH patients could be eligible for rFVIIa treatment each year. Such an impressive figure is expected to raise both organisational and financial problems for health care services, but more than 1200 lives may be saved annually [52].

Finally, some concerns have been raised about a possible increase of perihaeatoma oedema because of rFVIIa-mediated enhanced thrombin generation, as thrombin has been implicated in the pathogenesis of oedema formation in acute ICH [13, 14]. However in this trial [51] the mean volume of ICH, perihaeatomal oedema and intraventricular haemorrhage at 72 h were significantly lower in the rFVII than in the placebo group (mean difference from placebo −11 ml, \( p = 0.003 \)), arguing against an oedema-enhancing effect of the haemostatic treatment.

In conclusion, rFVIIa must be viewed as a promising new therapeutic approach to ICH. Hopefully the ongoing phase III rFVIIa in Acute Hemorrhagic Stroke Treatment (FAST) trial will clarify some of these relevant issues, such as the most effective and safe dose and the potential interactions of rFVIIa with blood pressure control.

### Treatment of ICH in anticoagulated patients

ICH is the most fearful and potentially fatal complication of OAT. Although the incidence, time course and rate of haematoma expansion of OAT-ICH are not well defined, it seems reasonable to expect that a rapid restoration of the haemostatic ability will help to stop ongoing bleeding, thus preventing haematoma growth. Against this sensible approach stands the fear of thromboembolic complications because of discontinuation of antithrombotic therapy. The resultant of such opposite forces is often a null vector. In most cases the therapeutic approach is therefore restricted to simply waiting for the disappearance of the anticoagulant effect, even though this can last for several days.

Such a nihilistic approach is particularly astonishing as many guidelines suggest (although with weak strength of recommendations because of the lack of solid evidence) that patients with diagnosed warfarin-associated ICH should receive emergent reversal of anticoagulation [54–58]. However, lack of well designed trial of good methodological quality makes it very difficult to formulate strong recommendations, leaving the optimal treatment of OAT-ICH an already open issue. Treatment options include the use of vitamin K, fresh frozen plasma (FFP), prothrombin complex concentrates (PCC) and rFVIIa [38].

There is a general consensus on vitamin K administration as the first step of warfarin reversal, but as it takes several hours to achieve its full therapeutic effect, concomitant administration of coagulation factors is required in order to immediately reverse the anticoagulant effect. FFP contains all coagulation factors, and it is generally assumed that 1 ml/kg body weight of FFP increases the levels of coagulation factors by 1–2 IU [59]. It is a common experience that the FFP volume required to ensure anticoagulation reversal may vary between 800 and 3500 ml [19]. The latter large volumes may cause a circulatory overload, namely in patients with
impaired cardiac function, which represent a substantial proportion of warfarin-treated patients. FFP carries other drawbacks, such as the need for compatibility testing, the time required for thawing and a small, but definite, risk of adverse reactions, including transfusion-associated lung injury, blood-borne infections and allergic reactions [59].

Many of these problems can be overcome by PCC use. PCC contain coagulation factors II, IX, X and VII (the latter not in preparations licensed in Italy) in a concentrated form and in well standardised amounts. These products are virally inactivated, and therefore are safer than plasma with respect to the risk of transmission of the human immunodeficiency, hepatitis B or hepatitis C virus. A thrombogenic effect has occasionally been reported, but reports dealt with patients at very high thromboembolic risk [60]. Moreover, only a very small volume of product is required in order to ensure complete reversal of anticoagulation: a standard dose of 30–50 IU/kg of PCC consisted of 50–150 ml of reconstituted product, which can be administered within a few minutes.

Studies on small numbers of patients suggest that PCC correct a prolonged INR more rapidly and completely than FFP [61, 62] and reduce the risk for haematoma growth [61], although they does not appear to improve long-term outcome [63, 64].

The already reported biochemical features of rFVIIa make it a promising candidate also for OAT-ICH treatment, but so far the data on this subject are very limited [65, 66]. The very short half-life of rFVIIa can be a serious drawback for the treatment of bleeding in anticoagulated patients. Indeed, rFVIIa action is expected to stop long before the vitamin-K-dependent factors are restored, thus exposing patients to a potentially dangerous time window of persistent anticoagulation.

Patients with OAT-ICH urgently need a definitive improvement in the treatment of their severe complication. Very recently published data show that in Italy, only about a third of patients admitted to emergency departments with warfarin-related ICH undergo procoagulant medical treatment [67]. Moreover, a recently published retrospective review of a single-centre experience on the management of OAT-ICH found a strikingly long delay in time to intervention, as a median period of 210 min is required from computed tomography to FFP administration for patients referred from other hospitals [68]. The Authors found that every 30-min delay in FFP administration is independently associated with a 20% decrease in the probability of successful INR reversal within 24 h [68]. Once again, “Time is brain” [37], and each hospital should have protocols for the treatment of ICH, as they do for ischaemic stroke. Table 3 reports a protocol recently proposed by FCSA (Italian Federation of Anticoagulation Clinics) for the emergency management of ICH in anticoagulated patients.

Many issues remain to be clarified in OAT-ICH, and probably the most compelling is if and when to restart anticoagulation following the development of such a serious adverse effect of warfarin therapy. There is no strong scientific evidence that can help the physician in this difficult decision, which should be made on an individual patient basis, carefully balancing haemorrhagic and thromboembolic risks. As a rule, the risk of recurrence is considerably greater in lobar than in deep hemispheric ICH [69], reflecting a different underlying pathophysiology: hypertension in the former, and cerebral amyloid angiopathy in the latter [70]. The latter disorder is characterised by the deposition of

Table 3 Protocol for the emergency management of intracerebral haemorrhage in anticoagulated patients

| In anticoagulated patients with suspected/possible ICH: |
|--------------------------------------------------------|
| a. Provide a venous access of adequate size             |
| b. Provide a blood sampling for routine test, including:|
|   i. Blood count including platelet count               |
|   ii. Prothrombin time – International Normalised Ratio (PT-INR) |
|   iii. Activated partial thromboplastin time (APTT)     |
|   iv. Serum creatinine                                  |
| c. Perform a cerebral computed tomography (CT) in every symptomatic case or following head trauma. The CT should be repeated after a few days if negative or in case of persistent/arising symptoms. |
| d. If the CT is positive for intracranial haemorrhage it is MANDATORY to immediately restore normal haemostasis. Then: |
|   i. Withhold warfarin therapy                          |
|   ii. Give vitamin K1 (10 mg by slow IV infusion)       |
|   iii. Give prothrombin complex concentrates at the following doses: |
|     1. 20 IU/kg if INR<2.0                               |
|     2. 30 IU/kg if INR 2.0–4.0                          |
|     3. 50 IU/kg if INR >4.0                             |
|   iv. If PCC are unavailable, give fresh frozen plasma 15–20 ml/kg. In this case, consider the concomitant administration of diuretics in order to prevent circulatory overload. |
|   v. Control PT-INR at the end of the infusion and repeat PCC (or FFP) if PT-INR>1.5 |
|   vi. Provide prophylaxis of venous thromboembolism by mechanical methods (graduated compression stockings or intermittent pneumatic compression) |

The decision of if, and when, to restart anticoagulation should be made on an individual patient basis, carefully balancing thromboembolic and bleeding risk. As a rule, prophylactic doses of low molecular weight heparins can be safely administered after 3 days and following a normal CT scan.
amyloid peptide in small- and medium-sized blood vessels of the brain, thus resulting in vascular fragility. The clinical syndrome is typified by spontaneous lobar haemorrhage in elderly patients, usually less severe than hypertensive ICH. However, the recurrence rate is considerably higher in patients with lobar ICH and probable amyloid angiopathy (5%–15% patients/year) than in those with hypertensive ICH (2%/year when blood pressure is well controlled).

On these grounds it would seem reasonable to advise against restarting OAT following a lobar ICH. However, this does not mean that for the vast majority of patients with deep hemispheric haemorrhage anticoagulation therapy can be recommended, with a possible exception for patients at very high risk of ischaemic stroke [71].

Further clarification of risk factors for developing OAT-ICH may help to clarify the risk-benefit analysis of warfarin administration in individual patients. Genetic risk factors may have a role in this effort, as the possession of apolipoprotein E (apoE) ε2 or ε4 allele appears to be associated with increased risk of lobar ICH and recurrent ICH resulting from cerebral amyloid angiopathy [72]. In addition, genetic polymorphisms have been identified that predispose to decreased dose requirements for warfarin and may predispose to increased risk for high INR [73, 74]. Finally, remember the profound influence of blood pressure control upon the prevention of ICH. In a recently published randomised trial involving patients on either antiplatelet or anticoagulant therapy, haemorrhagic stroke rate is halved by a mean 9 mmHg reduction in systolic blood pressure [75]. This very simple and inexpensive intervention is the first proven preventive therapy for patients with a history of haemorrhagic events, and should therefore be extended to every patient receiving antithrombotic drugs.

Conclusions

Many issues regarding the appropriate treatment of ICH need to be clarified by properly designed trials. Nevertheless, there is a growing body of literature providing new insights into this serious disease and giving new realistic hopes to ICH patients. The goal of substantially improving the outcome of this dreadful disease is certainly demanding, but is now more feasible than a few years ago.

References

1. Sacco RL, Mayer SA (1994) Epidemiology of intracerebral hemorrhage. In: Feldmann E (ed) Intracerebral hemorrhage. Futura Publishing Co, New York, pp 3–23
2. Taylor TN, Davis PH, Torner JC et al (1996) Lifetime cost of stroke in the United States. Stroke 27:1459–1466
3. Broderick JP, Adams HP Jr, Barsan W et al (1999) Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 30:905–915
4. Gebel JM, Broderick JP (2000) Intracerebral hemorrhage. Neurocar Clin 18:419–438
5. Qureshi AI, Tuhrim S, Broderick JP et al (2001) Spontaneous intracerebral hemorrhage. N Engl J Med 344:1450–1460
6. Hart RG, Tonarelli SB, Pearce LA (2005) Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 36:1588–1593
7. Brott T, Broderick J, Kothari R et al (1997) Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 28:1–5
8. Fujii Y, Tanaka R, Takeuchi S (1994) Hematoma enlargement in spontaneous intracerebral hemorrhage. J Neurosurg 80:51–57
9. Kazui S, Naritomi H, Yamamoto H et al (1996) Enlargement of spontaneous intracerebral hemorrhage: incidence and time course. Stroke 27:1783–1787
10. Hemphill JC III, Bonovich DC, Besmeris L et al (2001) The ICH Score. A simple, reliable grading scale for intracerebral hemorrhage. Stroke 32:891–897
11. Mayer SA (2003) Ultra-early hemostatic therapy for intracerebral hemorrhage. Stroke 34:224–229
12. Lee KR, Colon GP, Betz AL et al (1996) Edema from intracerebral hemorrhage: the role of thrombin. J Neurosurg 84:91–96
13. Lee KR, Kawai N, Kim S et al (1997) Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood–brain barrier permeability, and cell survival in a rat model. J Neurosurg 86:272–278
14. Xi G, Keep RF, Hoff JT (2002) Pathophysiology of brain edema formation. Neurosurg Clin N Am 13:371–383
15. Franke CL, de Jonge J, van Swieten JC et al (1990) Intracerebral hematomas during anticoagulant treatment. Stroke 21:726–730
16. Hart RG, Boop BS, Anderson DC (1995) Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 26:1471–1477
17. Palareti G, Leali N, Coccheri S et al (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348:423–428
18. Nicolini A, Ghirarduzzi A, Iorio A et al (2002) Intracranial bleeding: epidemiology and relationships with antithrombotic treatment in 241 cerebral hemorrhages in Reggio Emilia. Haematologica 87:948–956
19. Steiner T, Rosand J, Diringer M (2006) Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 37:256–262
20. Hylek EM, Go AS, Chang Y et al (2003) Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349:1019–1026
21. Fang MC, Chang Y, Hylek EM et al (2004) Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 141:745–752
22. Rosand J, Eckman MH, Knudsen KA et al (2004) The effect of warfarin and intensity of anticoagulation on out-
come of intracerebral hemorrhage. Arch Intern Med 164:880–884
23. – (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449–1457
24. Stroke Prevention in Atrial Fibrillation Investigators (1996) Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 156:409–416
25. Fibbotte JI, Hagan N, O’Donnell J et al (2004) Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 63:1059–1064
26. Diener HC, Bogousslavsky J, Pass LM et al (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double blind, placebo-controlled trial. Lancet 364:331–337
27. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502
28. Saloheimo P, Ahonen M, Juvela S et al (2006) Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke 37:129–133
29. Nilsson OG, Lindgren A, Brandt L, Säveland H (2002) Prediction of death in patients with primary intracerebral hemorrhage: a prospective study of a defined population. J Neurosurg 97:531–536
30. Toyoda K, Okada Y, Minematsu K et al (2005) Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology 65:1006–1004
31. Foerch C, Sitzer M, Steinmetz H, Neumann-Haefelin T for the Arbeitsgruppe Schlaganfall Hessen (2006) Pretreatment with antiplatelet agents is not independently associated with unfavorable outcome in intracerebral hemorrhage. Stroke 37:2165–2167
32. Howard PA, Ellerbeck EF, Engelmann KK, Patterson KL (2002) The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiol Drug Saf 11:569–576
33. Hart RG, Benavente O, Pearce LA (1999) Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis 9:215–217
34. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF (2004) Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 35:2362–2367
35. Berwaerts J, Webster J (2000) Analysis of risk factors involved in oral-anticoagulant-related intracranial hemorrhages. Q J Med 93:513–521
36. Fang MC, Chang Y, Hylek EM et al (2004) Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 141:745–752
37. Hemphill JC III (2006) Treating warfarin-related intracerebral hemorrhage. Is fresh-frozen plasma enough? Stroke 37:6–7
38. Mayer SA, Rincon F (2005) Treatment of intracerebral haemorrhage. Lancet Neurol 4:662–672
39. Qureshi AI, Bliwise DL, Bliwise NG et al (1999) Rate of 24-hour blood pressure decline and mortality after spontaneous intracerebral haemorrhage: a retrospective analysis with a random effects regression model. Crit Care Med 27:480–485
40. Willmot M, Leonardi-Bee J, Bath PMW (2004) High blood pressure in acute stroke and subsequent outcome: a systematic review. Hypertension 43:18–24
41. Jauch EC, Lindell CI, Adeoye O et al (2006) Lack of evidence for an association between hemodynamic variables and hematoma growth in spontaneous intracerebral hemorrhage. Stroke 37:2061–2065
42. Cottrell JE, Patel K, Turndorf H, Ransohoff J (1978) Intracranial pressure changes induced by sodium nitroprise- side in patients with intracranial mass lesions. J Neurosurg 48:329–331
43. Poungvarin N, Bhoopat W, Viriyavejakul A et al (1987) Effects of dexamethasone in primary supratentorial intracerebral hemorrhage. N Engl J Med 316:1229–1233
44. Yu YL, Kumana CR, Lauder IJ et al (1992) Treatment of acute cerebral hemorrhage with intravenous glycerol: a double-blind, placebo-controlled, randomised trial. Stroke 23:967–971
45. Italian Acute Stroke Study Group (1988) Haemodilution in acute stroke: results of the Italian haemodilution trial. Lancet 1:318–321
46. Mendelow AD, Gregson BA, Fernandes HM et al; STICH Investigators (2005) Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 365:387–397
47. Franchini M, Zaffanello M, Veneri D (2005) Recombinant factor VIIa: An update on its clinical use. Thromb Haemost 93:1027–1035
48. Abshire T, Kenet G (2004) Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2:899–909
49. Mayer SA, Brun NC, Begtrup K et al for the Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators (2005) Recombinant activated factor VII for the treatment of patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. N Engl J Med 352:777–785
50. You H, Al-Shani R (2006) Haemostatic drug therapies for acute primary intracerebral haemorrhage. Cochrane Database Syst Rev 2006 Jul 19;3:CD005951
51. Juvela S, Kase CS (2006) Advances in intracerebral hemor- rhage management. Stroke 37:301–304
52. Flaherty ML, Woo D, Haverbusch M et al (2005) Potential applicability of recombinant factor VIIa for intracerebral hemorrhage. Stroke 36:2660–2664
53. Kleindorfer D, Kissela B, Schneider A et al (2004) Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke 35:e27–e29
54. British Committee for Standards in Haematology (1998) Guidelines on oral anticoagulation: third edition. Br J Haematol 101:374–387
55. Scottish Intercollegiate Guidelines Network (1999) Antithrombotic therapy. SIGN Publication Number 36, March
56. Hanley JP (2004) Warfarin reversal. J Clin Pathol 57:1132–1139
57. Baker RI, Coughlin PB, Gallus AS et al (2004) Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thromb Haemost. Med J Aust 181:492–497

58. Ansell J, Hirsh J, Poller L et al (2004) The pharmacology and management of the vitamin K antagonists. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:204S–233S

59. O’Shaughnessy DF, Atterbury C, Bolton Maggs P et al (2004) Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 126:11–28

60. Kohler M, Hellstern P, Lechler E et al (1998) Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost 80:399–402

61. Makris M, Greaves M, Phillips WS et al (1997) Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 77:477–480

62. Boullis NM, Bobek MP, Schmaier A, Hoff JT (1999) Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 45:1113–1118

63. Huttner HB, Schelling PD, Hartmann M et al (2006) Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy. Comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 37:1465–1470

64. Sjöblom L, Hardemark HG, Lindgren A et al (2001) Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 32:2567–2574

65. Sørensen B, Johansen P, Nielsen GL et al (2003) Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 14:469–477

66. Freeman WD, Brott TG, Barrett KM et al (2004) Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 79:1495–1500

67. Baldi G, Altomonte F, Altomonte M et al (2006) Intracranial haemorrhage in patients on antithrombotics: clinical presentation and determinants of outcome in a prospective multicentric study in Italian emergency departments. Cerebrovasc Dis 22:286–293

68. Goldstein JN, Thomas SH, Frontiero V et al (2006) Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 37:151–155

69. Bailey RD, Hart RG, Benavente O, Pearce LA (2001) Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology 56:773–777

70. Rosand J, Hylek EM, O’Donnell HC, Greenberg SM (2000) Warfarin associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology 55:947–951

71. Eckman MH, Rosand J, Knudsen KA et al (2003) Can patients be anticoagulated after intracerebral hemorrhage?: A decision analysis. Stroke 34:1710–1716

72. O’Donnell HC, Rosand J, Knudsen KA et al (2000) Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 342:240–245

73. Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717–719

74. Higashi MK, Veenstra DL, Kondo LM et al (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287:1690–1698

75. Chapman N, Huxley R, Anderson C et al (2004) Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history. The PROGRESS Trial. Stroke 35:116–121